Close

Roth Capital Remains Positive on Spectrum Pharma (SPPI) as Beleodaq Wins Accelerated Approval

July 7, 2014 7:20 AM EDT Send to a Friend
Roth Capital affirms Spectrum Pharma (Nasdaq: SPPI) at Buy with a price target of $15 following news that Beleodaq received ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login